SCHEMBL2675904

SCHEMBL2675904

O=CN1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 3/20 0.39
TSHR P16473 1/20 0.38
P4HB P07237 1/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
HTT P42858 2/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 6/20 0.36
HTR7 P34969 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HPGD P15428 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676745 0.97 NPSR1 (0.39) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2676766 0.88 MCL1 (0.46) MAPK1NPSR1L3MBTL1MAPTKDM4E
SCHEMBL2675569 0.88 ALDH1A1 (0.46) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2676392 0.88 MAPK1 (0.45) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2677324 0.87 MAPT (0.51) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2675780 0.87 ALDH1A1 (0.48) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2677517 0.86 ALDH1A1 (0.47) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2676750 0.86 ALDH1A1 (0.47) MAPK1NPSR1L3MBTL1MAPTTSHR
SCHEMBL2676988 0.86 ALDH1A1 (0.43) MAPK1NPSR1L3MBTL1MAPTHSP90AA1
SCHEMBL2677561 0.86 ALDH1A1 (0.42) MAPK1NPSR1L3MBTL1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MAPK1 2750/4885NPSR1 182/4885L3MBTL1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.